Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Glioblastoma 108Brain Neoplasms 106Glioma 83Neuroblastoma 34Astrocytoma 26Neoplasms 25Medulloblastoma 25Central Nervous System Neoplasms 25Neurofibromatosis 1 23Meningioma 23Ependymoma 22Sarcoma 21Breast Neoplasms 18Rhabdoid Tumor 16Melanoma 16Neurofibroma, Plexiform 15Carcinoma, Non-Small-Cell Lung 15Osteosarcoma 14Wilms Tumor 13Rhabdomyosarcoma 13Thyroid Neoplasms 12Sarcoma, Ewing 12Hepatoblastoma 12Gliosarcoma 12Recurrence 11Diffuse Intrinsic Pontine Glioma 11Pheochromocytoma 10Pancreatic Neoplasms 10Neoplasm Metastasis 10Ovarian Neoplasms 9

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × CNS × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡